YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer

PD-1 and PD-L1 antibodies have brought about extraordinary clinical benefits for cancer patients, and their indications are expanding incessantly. Currently, most PD-1/PD-L1 agents are administered intravenously, which may be uncomfortable for some cancer patients. Herein, we develop a novel oral-de...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Fangfang, Ji, Ming, Huang, Lei, Wang, Yunchen, Xue, Nina, Du, Tingting, Dong, Kai, Yao, Xiaoqing, Jin, Jing, Feng, Zhiqiang, Chen, Xiaoguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214057/
https://www.ncbi.nlm.nih.gov/pubmed/35755282
http://dx.doi.org/10.1016/j.apsb.2022.02.031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214057/
https://www.ncbi.nlm.nih.gov/pubmed/35755282
http://dx.doi.org/10.1016/j.apsb.2022.02.031

Ejemplares similares